Immix Biopharma (IMMX) Share-based Compensation (2021 - 2026)
Quarterly results put Share-based Compensation at $508065.0 for Q1 2026, up 16.88% from a year ago — trailing twelve months through Mar 2026 was $1.6 million (down 17.38% YoY), and the annual figure for FY2025 was $2.4 million, down 19.16%.
Immix Biopharma has reported Share-based Compensation over the past 6 years, most recently at $508065.0 for Q1 2026.
- Share-based Compensation reached $508065.0 in Q1 2026 per IMMX's latest filing, down from $570796.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.1 million in Q4 2023 and bottomed at $65074.0 in Q1 2022.
- Median Share-based Compensation over the past 5 years was $329919.0 (2023), compared with a mean of $380630.9.
- The largest annual shift saw Share-based Compensation surged 1432.23% in 2022 before it crashed 74.46% in 2025.
- Over 5 years, Share-based Compensation stood at $82771.0 in 2022, then skyrocketed by 1169.54% to $1.1 million in 2023, then tumbled by 32.85% to $705653.0 in 2024, then fell by 19.11% to $570796.0 in 2025, then fell by 10.99% to $508065.0 in 2026.
- Business Quant data shows Share-based Compensation for IMMX at $508065.0 in Q1 2026, $570796.0 in Q4 2025, and $402971.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 257.40 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - | 508,065.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 508,065.00 |
| Mar 31, 2026 | 508,065.00 |
| Dec 31, 2025 | 570,796.00 |
| Dec 31, 2025 | 570,796.00 |
| Sep 30, 2025 | 402,971.00 |
| Sep 30, 2025 | 402,971.00 |
| Jun 30, 2025 | 75,046.00 |
| Jun 30, 2025 | 75,046.00 |
| Mar 31, 2025 | 434,701.00 |
| Mar 31, 2025 | 434,701.00 |
| Dec 31, 2024 | 705,653.00 |
| Dec 31, 2024 | 705,653.00 |
| Sep 30, 2024 | 450,299.00 |
| Sep 30, 2024 | 450,299.00 |
| Jun 30, 2024 | 293,802.00 |
| Jun 30, 2024 | 293,802.00 |
| Mar 31, 2024 | 943,264.00 |
| Mar 31, 2024 | 943,264.00 |
| Dec 31, 2023 | 1.05 Mn |
| Dec 31, 2023 | 1.05 Mn |
| Sep 30, 2023 | 171,454.00 |
| Sep 30, 2023 | 171,454.00 |
| Jun 30, 2023 | 157,202.00 |
| Jun 30, 2023 | 157,202.00 |
| Mar 31, 2023 | 329,919.00 |
| Mar 31, 2023 | 329,919.00 |
| Dec 31, 2022 | 82,771.00 |
| Dec 31, 2022 | 82,771.00 |
| Sep 30, 2022 | 163,192.00 |
| Sep 30, 2022 | 163,192.00 |
| Jun 30, 2022 | 65,709.00 |
| Jun 30, 2022 | 65,709.00 |
| Mar 31, 2022 | 65,074.00 |
| Mar 31, 2022 | 65,074.00 |
| Dec 31, 2021 | 122,152.00 |
| Dec 31, 2021 | 122,152.00 |
| Sep 30, 2021 | 61,860.00 |
| Sep 30, 2021 | 61,860.00 |
| Jun 30, 2021 | 30,724.00 |
| Jun 30, 2021 | 30,724.00 |
| Mar 31, 2021 | 4,247.00 |
| Mar 31, 2021 | 4,247.00 |